Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The clinical activity and favorable toxicity profile of osimertinib has led it to be approved not only for advanced non-small cell lung cancer (NSCLC) patients with T790M-positive tumors when first, or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment fails, but also for untreated advanced NSCLC patients with EGFR sensitizing mutation, so how to manage patients who get acquired resistance to osimertinib has becoming an emerging clinical challenge. This presentation would report a case of an advanced NSCLC patient with EGFR 19DEL who received combination therapy of toripalimab and chemotherapy after resistance to first line osimertinib therapy and achieved a PFS benefit of over 8 months. This case highlighted that immune checkpoint blockade combined chemotherapy might be a new possibility for advanced NSCLC patients with acquired resistance to osimertinib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225156 | PMC |
| http://dx.doi.org/10.21037/tlcr.2020.02.09 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.
Drug Dev Res
September 2025
R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with "epidermal growth factor receptor (EGFR)" mutations playing a pivotal role in tumor progression and carcinogenesis. "Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)," such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the T790M mutation. However, Osimertinib's clinical application is limited by cardiotoxicity concerns, necessitating safer alternatives.
View Article and Find Full Text PDFLeveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects.
RSC Med Chem
August 2025
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University 4.5 Km the Ring Road Ismailia 41522 Egypt.
Protein kinases are central regulators of cell signaling and play pivotal roles in a wide array of diseases, most notably cancer and autoimmune disorders. The clinical success of kinase inhibitors-such as imatinib and osimertinib-has firmly established kinases as valuable drug targets. However, the development of selective, potent inhibitors remains challenging due to the conserved nature of the ATP-binding site, off-target effects, resistance mutations, and patient-specific variability.
View Article and Find Full Text PDFIdentifying meaningful drug response biomarkers from public pharmacogenomic datasets with biologically informed interpretable neural networks.
Comput Biol Chem
September 2025
Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macao Special Administrative Region of China. Electronic address:
With the advancements of next-generation sequencing, publicly available pharmacogenomic datasets from cancer cell lines provide a handle for developing predictive models of drug responses and identifying associated biomarkers. However, many currently available predictive models are often just used as black boxes, lacking meaningful biological interpretations. In this study, we made use of open-source drug response data from cancer cell lines, in conjunction with KEGG pathway information, to develop sparse neural networks, K-net, enabling the prediction of drug response in EGFR signaling pathways and the identification of key biomarkers.
View Article and Find Full Text PDFImpact of rare EGFR exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small-cell lung cancer: a 5-year multicenter analysis.
ESMO Open
September 2025
Department of Pulmonary and Critical Care Medicine, Fuzong Clinical Medical College of Fujian Medical University & The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, China. Electronic address:
Background: The clinical impact of rare epidermal growth factor receptor (EGFR) exon 19 insertion-deletion (19delins) variants on tyrosine kinase inhibitor (TKI) efficacy remains poorly characterized. We updated 5-year outcomes to evaluate long-term survival and optimal treatment strategies in advanced lung adenocarcinoma (LUAD) patients harboring these mutations.
Materials And Methods: In this multicenter prospective study, 36 treatment-naive advanced LUAD patients with EGFR 19delins mutations received first-generation (n = 26) or third-generation TKIs (n = 10).
A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition.
Int J Nanomedicine
September 2025
Department of Thoracic Surgery, Tenth Affiliated Hospital, Southern Medical University (Dongguan People's hospital), Dongguan, Guangdong, 523059, People's Republic of China.
Purpose: Osimertinib, established as the frontline treatment for advanced non-small cell lung cancer (NSCLC), can effectively prolong progression-free survival. However, it faces the problem of reduced treatment persistence due to acquired drug resistance. Meanwhile, tumor hypoxia is also a key driver of drug resistance.
View Article and Find Full Text PDF